Issue link: https://www.e-digitaleditions.com/i/1481142
34 OctOber 2022 Inhalation Integrated solutions for pulmonary and nasal drug delivery Catalent offers integrated solutions for pulmonary and nasal drug delivery, with clinical- to commercial- scale development and manufacturing capabilities for dry powder inhalers, unit-dose, bi-dose and pre- served multi-dose nasal sprays. With more than 30 years of experience, Catalent's team of inhalation experts provides scalable, reliable solutions to sup- port a molecule from development through product launch and beyond. Catalent US: + 1 888 SOLUTION (765-8846) www.catalent.com Inhaled drug delivery services Vectura is a provider of innovative inhaled drug deliv- ery services. With more than 20 years' experience, the company helps customers succeed in bringing inhaled medicines to market. With differentiated proprietary technology and pharmaceutical development exper- tise, Vectura is among the companies globally that have the device, formulation and development capa- bilities to deliver a broad range of complex inhaled therapies across a variety of platforms, including dry powder inhalers (DPIs), pressurised metered dose inhalers (pMDIs) and smart nebulizers. Vectura US: +44 1249 667700 info@vectura.com https://www.vectura.com Design, development and manufacture Recipharm has a long history in the design, develop- ment and manufacture of drug products and drug delivery devices, including inhalers and nasal tech- nologies. Product characterization is also part of its core capabilities including analytical method devel- opment, validation and testing services to support all phases of product development. Recipharm uses the latest technologies to generate aerosols suitable for inhalation and uses a variety of methods to analyze particle size including laser diffraction, microscopy, and spray pattern and plume geometry. By develop- ing products with the device and commercial man- ufacture in mind, Recipharm can eliminate hurdles and reduce time to market. Recipharm Sweden: +46 8 602 52 00 www.recipharm.com